1Glueck C J, Papanna R, Wang P, et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic overian syndrome. Metabolism, 2003,52: 908-915.
2Maciel GA, Soares Junior JM, Alves da Motta EL, et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril, 2004,81: 355-360.
3Mayerson AB, Hondal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes, 2002,51:797-802.
4Voberti G, kahn SE, Greene DA, et al. A Diabetes Outcome Progression Trial(ADOPT). An international muticenter study of the comparative efficacy of rosiglitazone, glyburide and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 2002,25: 1737-1743.
5Home PD, Gubb J. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes(RECORD): a long-term cardiovascular outcome study. Diabetes, 2002,51 (Suppl 2): A487.
6Tadayyon M, Swith SA. Insulin sensitization in the treatment of type 2 diabetes. Expert Opin Invest Drugs,2003,12:307-324.
7Zinker BA, Xie N, Clampit JE, et al. Anti-diabetic effects of protein tyrosine phosphatase 1B antisense treatment in a rodent model of diabetes:potential therapeutic benefit. Diabetes, 2001,50 (Suppl 2): A1378.
8Rask E, Olsson T, Soderberg S, et al. Impaired incretin response after a mixed meal is associated with insulin resistance in non-diabetic men. Diabetes Care,2001,24:1640-1645.
9Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of GLP-1 on glycaemic control, insulin sensitivity, and β-cell function in type-2 diabetes. Lancet, 2002,359: 824-830.
10Meneilly GS, Mclntosh CH, Pederson RA, et al. GLP-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.J Gerontol A Biol Med Sci, 2001,56: M681-M685.
